Fgfr2 - fibroblast growth factor receptor 2 Gene

中文名称：成纤维细胞生长因子受体 2

种属: Rattus norvegicus

基因 ID: 25022 | 基因类型: protein coding

关于 Fgfr2

Primary_assembly 1: 184,745,420-184,850,626 reverse strand.mRatBN7.2:CM026974.1

This gene has 4 transcripts (splice variants), 221 orthologues, 54 paralogues and is associated with 75 phenotypes. Biased expression in Adrenal (RPKM 15.3), Lung (RPKM 131.4) and 9 other tissues.

功能概要

该基因编码的蛋白可启动成纤维细胞生长因子结合活性和成纤维细胞生长因子激活受体活性。参与多个过程，包括细胞对生长因子刺激的反应；细胞对视黄酸的反应；和平滑肌细胞增殖的正调节。位于细胞表面；细胞质；和核。用于研究前列腺癌和视网膜色素变性。尿道下裂的生物标志物。该基因的人类直系同源基因与多种疾病有关，包括 Beare-Stevenson 皮肤回旋综合症； Jackson-Weiss 综合症； LADD 综合症；无性细胞瘤;和缝合早闭（多个）。与人 FGFR2（成纤维细胞生长因子受体 2）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables Fibroblast Growth Factor binding activity and fibroblast growth factor-activated receptor activity. Involved in several processes, including cellular response to growth factor stimulus; cellular response to retinoic acid; and positive regulation of smooth muscle cell proliferation. Located in cell surface; cytoplasm; and nucleus. Used to study prostate Cancer and retinitis pigmentosa. Biomarker of hypospadias. Human ortholog(s) of this gene implicated in several diseases, including Beare-Stevenson cutis gyrata syndrome; Jackson-Weiss syndrome; LADD syndrome; dysgerminoma; and synostosis (multiple). Orthologous to human FGFR2 (Fibroblast Growth Factor receptor 2). [provided by Alliance of Genome Resources, Apr 2022]

Fgfr2 基因产物(6)

mRNA	Protein	Name
NM_001109892.1	NP_001103362.1	fibroblast growth factor receptor 2 isoform b
NM_001109895.1	NP_001103365.1	fibroblast growth factor receptor 2 isoform e
NM_001109896.1	NP_001103366.1	fibroblast growth factor receptor 2 isoform f
NM_001109893.1	NP_001103363.1	fibroblast growth factor receptor 2 isoform c
NM_001109894.1	NP_001103364.1	fibroblast growth factor receptor 2 isoform d
NM_012712.1	NP_036844.1	fibroblast growth factor receptor 2 isoform a

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables fibroblast growth factor binding	IDA IDA: 通过直接分析推断	15282342	RGD
enables fibroblast growth factor binding	IPI IPI: 通过物理相互作用推断	7803853	RGD
enables fibroblast growth factor receptor activity	IDA IDA: 通过直接分析推断	15282342	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in cellular response to fibroblast growth factor stimulus	IEP IEP: 通过表达模式推断	9373031	RGD
involved in cellular response to fibroblast growth factor stimulus	IMP IMP: 通过突变表型推断	28981091	RGD
involved in cellular response to hypoxia	IEP IEP: 通过表达模式推断	31093967	RGD
involved in cellular response to retinoic acid	IEP IEP: 通过表达模式推断	15389522	RGD
involved in cellular response to transforming growth factor beta stimulus	IEP IEP: 通过表达模式推断	12648559	RGD
involved in endochondral bone growth	IEP IEP: 通过表达模式推断	17169623	RGD
involved in epithelial to mesenchymal transition	IDA IDA: 通过直接分析推断	7803853	RGD
involved in fibroblast growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	15282342	RGD
involved in fibroblast growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	15292181	RGD
involved in mesodermal cell differentiation	IEP IEP: 通过表达模式推断	7803853	RGD
involved in negative regulation of epithelial cell proliferation	IDA IDA: 通过直接分析推断	9537256	RGD
involved in positive regulation of vascular associated smooth muscle cell proliferation	IMP IMP: 通过突变表型推断	15292181	RGD
involved in response to ethanol	IEP IEP: 通过表达模式推断	16770775	RGD
involved in response to lipopolysaccharide	IEP IEP: 通过表达模式推断	19524256	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cell surface	IDA IDA: 通过直接分析推断	15614790	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Fgfr2 蛋白结构

IgI_2_FGFR

PTKc_FGFR2

0
200
400
600
841 a.a.

蛋白主名

其他名称

fibroblast growth factor receptor 2

相关产品

Approval

生物活性分子 (6)

目录号	产品名	作用方式	纯度	是否罕见病
HY-13311	Infigratinib		99.82%	是
HY-109099	Pemigatinib	Inhibitor	99.84%	是
HY-100818	Futibatinib	Inhibitor	99.65%	否
HY-N0060	Ferulic acid	Inhibitor	99.97%	是
HY-13311A	Infigratinib phosphate	Inhibitor	99.59%	是
HY-N0060A	Ferulic acid sodium	Inhibitor	99.88%	是

Clinical Phase

生物活性分子 (14)

目录号	产品名	作用方式	纯度	Phase
HY-13330	Fexagratinib	Inhibitor	99.85%	Phase 3
HY-100019	Rogaratinib	Inhibitor	99.86%	Phase 3
HY-19981	Derazantinib	Inhibitor	99.19%	Phase 3
HY-15391	Lucitanib	Inhibitor	98.94%	Phase 3
HY-13034	Gandotinib	Inhibitor	99.86%	Phase 2
HY-13304	LY2874455	Inhibitor	99.14%	Phase 2
HY-19957	Zoligratinib	Inhibitor	99.76%	Phase 2
HY-10987A	ENMD-2076		99.99%	Phase 2
HY-10186	TG 100801	Inhibitor	98.61%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.66%	Phase 2
HY-101466A	E7090 succinate	Inhibitor	99.17%	Phase 2
HY-10187	TG 100801 Hydrochloride	Inhibitor	/	Phase 2
HY-101768	PRN1371	Inhibitor	99.78%	Phase 1
HY-156632	Resigratinib	Inhibitor	99.53%	Phase 1

抗体抑制剂 (2)

目录号	产品名	作用方式	纯度	Phase
HY-P99010	Bemarituzumab	Inhibitor	99.82%	Phase 3
HY-P99007	Aprutumab	Inhibitor	99.00%	Phase 1

Pre-clinical Phase

生物活性分子 (56)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-N0183	Formononetin		98.99%	否
HY-147250	Lirafugratinib	Inhibitor	99.67%	否
HY-17601	Alofanib		99.90%	否
HY-18602	FIIN-2	Inhibitor	99.32%	否
HY-145231	FGFR2-IN-2	Inhibitor	98.25%	否
HY-15813	FIIN-1	Inhibitor	99.11%	否
HY-101466	E7090	Inhibitor	98.11%	否
HY-148779	FGFR3-IN-5	Inhibitor	99.16%	否
HY-N7715	Ferulic acid acyl-β-D-glucoside		99.33%	否
HY-149843	LC-MB12		99.23%	否
HY-128979	Deruxtecan analog 2		99.56%	否
HY-10185	TG 100572 Hydrochloride	Inhibitor	98.76%	否
HY-18603	FIIN-3	Inhibitor	99.66%	否
HY-147250A	Lirafugratinib hydrochloride	Inhibitor	98.96%	否
HY-145230	FGFR2-IN-1	Inhibitor	99.78%	否
HY-13311S	Infigratinib-d3	Inhibitor	98.90%	否
HY-145043	FGFR-IN-1	Inhibitor	99.46%	否
HY-162865	FGFR2-IN-3	Inhibitor	98.28%	否
HY-10184	TG 100572	Inhibitor	/	否
HY-19981B	Derazantinib dihydrochloride	Inhibitor	/	否
HY-101544	ARQ 069	Inhibitor	/	否
HY-117595	PHM16		/	否
HY-123134	FIIN-4	Inhibitor	/	否
HY-141685	3-Methylthienyl-carbonyl-JNJ-7706621	Inhibitor	/	否
HY-142921	FGFR-IN-2	Inhibitor	/	否
HY-146541	FGFR4-IN-10	Inhibitor	/	否
HY-148597	FGFR-IN-10	Inhibitor	/	否
HY-150652	FGFR-IN-8		/	否
HY-151903S	FGFR2/3-IN-1	Inhibitor	/	否
HY-152104	FGFR-IN-9	Inhibitor	/	否
HY-152146	HDAC-IN-50		/	否
HY-155028	FGFR-IN-11	Inhibitor	/	否
HY-162577	FGFR-IN-14	Inhibitor	/	否
HY-162626	FGFR2 degrader 1	Degrader	/	否
HY-163273	FGFR4-IN-17	Inhibitor	/	否
HY-163620	LHQ490		/	否
HY-163985	PROTAC FGFR2 degrader 1		/	否
HY-163986	Pomalidomide-C2-NHCO-C6		/	否
HY-163989	N-Ethylheptanamide		/	否
HY-168286	FGFR-IN-16	Inhibitor	/	否
HY-170919	FGFR2/3-IN-2	Inhibitor	/	否
HY-170934	BW710	Inhibitor	/	否
HY-172916	LC-SF-14	Inhibitor	/	否
HY-172921	FGFR-IN-18	Inhibitor	/	否
HY-172922	FGFR-IN-19	Inhibitor	/	否
HY-172923	FGFR-IN-20	Inhibitor	/	否
HY-174154	INCB126503	Inhibitor	/	否
HY-176547	FGFR2/3-IN-3	Inhibitor	/	否
HY-N0060S1	Ferulic acid-13C3	Inhibitor	98.3%	否
HY-N9507	Picrasidine Q		/	否
HY-RS04915	FGFR2 Human Pre-designed siRNA Set A		/	否
HY-RS04916	Fgfr2 Mouse Pre-designed siRNA Set A	Pre-designed Set	/	否
HY-RS04917	Fgfr2 Rat Pre-designed siRNA Set A	Pre-designed Set	/	否
HY-15391A	Lucitanib dihydrochloride	Inhibitor	/	否
HY-159503A	Segigratinib hydrochloride	Inhibitor	/	否
HY-W754878	Pemigatinib-d6	Inhibitor	/	否

抗体抑制剂 (4)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P99010A	Bemarituzumab (FUT8-KO)	Inhibitor	99.74%	否
HY-141600	Aprutumab ixadotin		98.99%	否
HY-P991583	GP369	Inhibitor	/	否
HY-P991584	HuGAL-FR21	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Fgfr2	NCBI	NCBI:2263

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4